Stock for DBV Technologies S.A. (NASDAQ: DBVT) remained relatively stable throughout the day and began climbing in the current market. After little movement during the regular session, DBVT stock steadily rose by an impressive 14.74%. Traders continue to anticipate whether or not this steady growth spurt shall continue upon this trajectory, as the premarket session continues. The market anticipates further growth, given the significantly noticeable gap which is likely to be filled in.
Chatter amongst traders on social media spheres indicates a degree of caution with which the market views this reversal. The bearish trend the stock has maintained since the prior year is cause for this widespread skepticism regarding the stock. However, the DBVT stock is currently part of a growth spurt that biotech and pharmaceutical firms have been recently experiencing. The healthcare sector is seeing a wide reallocation of financing, with the threat of the Covid-19 pandemic being seriously downgraded.
DBVT Participation in AAAAI Conference
Last month, DBV Technologies announced participation in the AAAAI Conference 2022, which will be held at the end of March. The American Academy of Allergy Asthma and Immunology is a prestigious platform likely to boost credibility in DBVT. The scientific presentations delivered by the company would include a clinical and a non-clinical poster, which is certain to bring DBVT under the spotlight. The company’s participation in the conference will shed light on peanut allergy treatment with respect to epinephrine prescription. The DBVT team will further highlight the variable of healthcare cost, within this critical discussion.
Viaskin Development and DBVT
During the course of the conference, DBVT will share crucial information regarding clinical trials on Viaskin. This is a product the company is currently developing to address peanut allergies. Given that peanut allergies constitute the most common allergic condition amongst American children, this could potentially be a breakthrough. Investors certainly realize the value addition this could contribute towards, something evident by the management’s optimism surrounding this treatment. Similarly, the growth trajectory undertaken by the DBVT stock could potentially be an indicator of this gleeful anticipation.
Conclusion
Retail investors are closely watching the DBVT stock, with many anticipating the realization of even bigger growth. This is presumably a part of a broader growth spurt the biopharmaceutical sector is currently witnessing. DBV Technology’s participation in the upcoming AAAAI Conference could further raise market perception towards the stock.
